16results about How to "Improving immunogenicity" patented technology

The application discloses a kind of avian influenza and avian infectious bronchitis two-union recombinant subunit vaccine and its preparation method and application.The recombinant protein is by replacing the head domain of AIV HA protein with the RBD domain of IBV S protein, while adding GCN4, Trimer-tag trimer tag in sequence, the recombinant protein obtained, the recombinant protein is expressed in vitro using insect cells and prepared into subunit vaccine.The vaccine prepared by the application can produce high-level neutralizing antibodies against homologous and heterologous H9N2 subtype avian influenza virus after immunizing chicken population, while significantly reducing the virus discharge level and the histopathological changes caused, and can also induce high-level specific antibodies and neutralizing antibodies against QX subtype avian infectious bronchitis virus, effectively inhibit discharge, viral load, and reduce tissue lesions.The application does not depend on chicken embryo, and has low production cost and short cycle, and can simultaneously prevent avian influenza and avian infectious bronchitis.

The invention belongs to the technical field of biological medicine, and particularly relates to a PDHC mutant, an immunogenic fragment and application, the PDHC mutant has amino acid mutation at at least one of the 214th site, the 274th site or the 294th site of the amino acid sequence shown in SEQ ID NO: 1, and the PDHC mutant is used for preventing or treating staphylococcus aureus (SA) infection and is an mRNA vaccine for preventing or treating staphylococcus aureus (SA) infection. The stability and immunogenicity of the staphylococcus aureus PDHC antigen are greatly improved, efficient targeted delivery of the antigen is achieved, and the immune effect of the vaccine is remarkably improved.

The present application relates to a kind of mycophenolic acid detection reagent and its preparation and detection method, specifically a kind of mycophenolic acid chemiluminescence immunoassay reagent and its preparation and detection method, comprising: anti mycophenolic acid specific antibody, for detecting the indicating reagent of anti mycophenolic acid specific antibody-mycophenolic acid combination;The above anti mycophenolic acid specific antibody is obtained by mycophenolic acid immunogen immunization animal.The present application has the advantages that: the mycophenolic acid immunogen of the present application is specific, and immunogenicity is high, and the prepared anti mycophenolic acid specific antibody is specific, and titer is high;Chemiluminescence immunoassay reagent containing the above anti mycophenolic acid specific antibody can determine the mycophenolic acid content in sample conveniently, quickly and accurately, and multiple samples can be simultaneously determined on full-automatic chemiluminescence immunoassay analyzer, realize the high-throughput rapid determination of mycophenolic acid, and the accuracy is high, and the specificity is strong, and accuracy and detection efficiency have been greatly improved.

The application provides a hybridoma cell strain secreting a monoclonal antibody against a alginate mannuronic acid tetrasaccharide epitope, a monoclonal antibody and application. In order to enhance the immunogenicity of the mannuronic acid tetrasaccharide, a glycoconjugate KLH-1 is used as an immunogen to inject and immunize a mouse, so that the mouse is stimulated to produce a specific immune response against the mannuronic acid tetrasaccharide epitope, then spleen cells of the immunized mouse are fused with myeloma cells, and after screening, an initial hybridoma cell strain is obtained; then after subcloning and specific screening, a hybridoma cell strain capable of stably secreting a monoclonal antibody of the target mannuronic acid tetrasaccharide epitope in alginate is obtained, and a monoclonal ascites antibody is further obtained. The monoclonal ascites antibody shows specific recognition and combination ability for pseudomonas aeruginosa, and the combination activity is related to the expression level of alginate on the surface of the bacteria. Therefore, the monoclonal ascites antibody can be used as a precise detection and diagnosis tool for pseudomonas aeruginosa, and can also be applied to the antibacterial treatment of pseudomonas aeruginosa infection.

This application relates to the field of antibody technology, specifically providing a truncated fragment of the African swine fever virus pB602L protein, an antibody thereof, or an antigen-binding fragment thereof, and their applications. The truncated fragment, encoded by SEQ ID NO.1, eliminates mismatched disulfide bonds and repetitive sequences by deleting the first 200 amino acids from the N-terminus, thereby improving protein solubility and immunogenicity. The antibody thereof or its antigen-binding fragment contains the heavy chain variable region shown in SEQ ID NO.2 and the light chain variable region shown in SEQ ID NO.4, exhibiting a blocking rate of greater than 90% against the pB602L protein. This truncated fragment and antibody demonstrate high specificity and sensitivity, and can be used for the detection, diagnosis, and evaluation of vaccine immunization efficacy for African swine fever virus, providing an important tool for the prevention and control of African swine fever.

This invention discloses a type B influenza virus T4 peptide that can induce cellular immune responses and its applications, belonging to the fields of immunotherapy and immunoassay technology. The immunogenicity of this long peptide (SEQ ID NO.1, named T4) was verified in 21 volunteers using ELISpot assay. Results showed that T4 was positive in 5 individuals, with a positive rate of 23.81%. ELISpot assay of human PBMCs (IFN-γ secretory cells) showed that T4 induced an immune response of up to 3060 SFCs / 10 in the population. 6 PBMC. Therefore, this peptide has good immunogenicity and universality in the population, and can be used as a specific detection peptide for monitoring cellular immune levels. At the same time, this peptide can effectively activate the T cell immune response in the population, and has the potential to be used as a candidate vaccine epitope peptide for the design of novel vaccines.

This invention provides a method for preparing influenza virus hemagglutinin protein HA and its application, belonging to the field of biopharmaceutical technology. The method utilizes engineered cell chassis cells with glycosylation modification capabilities. After fermentation expression, the expressed protein from the engineered cells is extracted in a single step to obtain a crude extract containing the target antigen. The crude extract obtained from the engineered cells constructed in this invention, after induction, has the potential to serve as a candidate for a dual-route vaccine (intramuscular injection and mucosal immunization), providing a new technical approach for the multi-route immunization development of influenza vaccines.

The application provides a pertussis antigen recombinant expression vector and engineering bacteria and application thereof. The pertussis antigen recombinant expression vector comprises a resistance screening gene, an upstream recombinant nucleic acid fragment of a pertussis exotoxin gene and a downstream recombinant nucleic acid fragment, wherein the upstream and downstream recombinant nucleic acid fragments can respectively perform homologous recombination with the upstream and downstream of the pertussis exotoxin gene. The application takes the pertussis bacillus as a host, constructs an engineering bacteria ΔPT strain for producing FHA and PRN by knocking out the PT gene, simplifies the production process of the FHA and PRN antigens, maintains the high purity and immunogenicity of the FHA and PRN antigens, eliminates the interference of the PT protein in the production of the FHA and PRN antigens, avoids the PT protein detoxification process, and eliminates the risk of possible PT protein toxicity reversal.

The application discloses a Candida albicans bivalent subunit vaccine fusion protein and a preparation method and application thereof, and relates to the technical field of biological medicines. The fusion protein is formed by connecting a Candida albicans Sap2 truncated fragment (SEQ ID NO: 1) and a Cht3 truncated fragment (SEQ ID NO: 2) through a flexible linker (SEQ ID NO: 3). The application further provides a nucleotide sequence encoding the fusion protein, a vaccine containing the fusion protein and a pharmaceutically acceptable adjuvant, and application of the fusion protein in preparation of a medicine or vaccine for preventing Candida albicans infection. The fusion protein is recombinantly expressed, enzymatically cut on a GST affinity chromatographic column and refined through ion exchange chromatography, and the purity can reach more than 95%. The fusion protein is significantly superior to a Sap2 and Cht3 physical mixing group, has an immune synergistic enhancement effect, and can be used for preventing Candida albicans infection.

This invention belongs to the field of veterinary biological products technology, specifically relating to a chicken-derived serum type 7 of *Rimerella anatipestifer* and its application. *Rimerella anatipestifer* (… Riemerella anatipestifer HD24 has been deposited at the China General Microbiological Culture Collection Center (CGMCC) on March 18, 2026, with accession number CGMCC No. 37707. The inactivated vaccine using the HD24 strain exhibits an 80% immunoprotective rate, demonstrating its good immunogenicity and safety. This provides an ideal candidate strain for the development of inactivated chicken rabies (RA) vaccines, addressing the current shortage and lack of specificity of chicken-derived RA vaccines, and offering a new technical solution for the proactive prevention and control of RA infection in chicken flocks.

The invention belongs to the technical field of biology, and discloses a method for determining a multivalent antigen sequence of an anti-periodontitis red complex, which comprises the following steps: firstly, screening out key virulence factor antigens (FimA-II, RgpA, Msp and BspA) from three core pathogenic bacteria of the red complex: porphyromonas gingivalis, treponema denticola and fusisterone; then, independently cloning each antigen gene to a pUC57 cloning vector, constructing a single antigen recombinant plasmid, and avoiding intergene interference by designing a specific enzyme cutting site; and finally, through plasmid transformation, positive clone screening and double enzyme digestion verification, the plasmid quality is ensured. The obtained single antigen plasmid can be flexibly combined and used, is beneficial to subsequent multivalent vaccine development, and has the advantages of wide antigen coverage, high expression reliability, flexible construction strategy, easiness in industrialization and the like.

The invention discloses a multi-epitope peptide of Ebola virus, a vaccine as well as a preparation method and application of the multi-epitope peptide and the vaccine, and belongs to the technical field of biological medicines. The multi-epitope peptide is derived from surface glycoprotein (Glycoprotein, GP) of Zaire type Ebola virus and Sudan type Ebola virus, and the epitope peptide is conserved in the two types of Ebola viruses. In addition, the multi-epitope peptide is both a T cell epitope and a B cell epitope. An epitope peptide and a nano delivery carrier are connected through a linker to prepare a vaccine, the vaccine comprises the multi-epitope peptide or a combination thereof, a free KFE8 self-assembly peptide and a PADRE-KFE8 fusion peptide, and a nano fiber structure is formed through self-assembly of the multi-epitope peptide or the combination thereof, the free KFE8 self-assembly peptide and the PADRE-KFE8 fusion peptide. The preparation method comprises the following steps: dissolving the components in a buffer solution according to a specific molar ratio, and incubating to enable the components to be self-assembled to form nanofibers. The multi-epitope peptide can be used for preparing a vaccine for preventing Ebola virus infection, and the vaccine can induce humoral immunity and cellular immunity at the same time, and has broad-spectrum protection potential for Zaire type and Sudan type Ebola viruses at the same time.

The invention relates to the technical field of antibodies, and particularly provides a truncated fragment of African swine fever virus C129R protein, an antibody or an antigen binding fragment of the antibody and application of the truncated fragment and the antibody. The amino acid sequence of the truncated fragment C129R delta C is coded by SEQ ID NO: 1, and the truncated fragment C129R delta C has improved immunogenicity. The antibody specifically bound with the C129R protein or the antigen binding fragment of the antibody comprises a heavy chain variable region as shown in SEQ ID NO: 2 and a light chain variable region as shown in SEQ ID NO: 4; the blocking rate of the monoclonal antibody 3C10 is higher than 90%. On the basis of the core material, a kit for detecting the indirect ELISA antibody and the blocking ELISA antibody is constructed. The two kits both show high sensitivity, high specificity and good repeatability, and an efficient and reliable tool is provided for serological detection of African swine fever.

This invention discloses a duck-derived recombinant infectious bronchitis virus and its applications, belonging to the field of viral isolation and application. The virus was deposited at the China Center for Type Culture Collection on December 26, 2024, with accession number CCTCC NO: V202503. The duck-derived recombinant infectious bronchitis virus of this invention is capable of infecting CEF and DEF cells, is convenient for in vitro culture, and is suitable for the production of high-quality inactivated vaccines with high antigen titers. The duck-derived recombinant infectious bronchitis virus DIBVSD2401 of this invention has excellent immunogenicity, and the inactivated vaccine prepared using the duck-derived recombinant infectious bronchitis virus DIBVSD2401 of this invention has good safety and excellent protective effect.

The application belongs to the technical field of biological detection, and discloses an anti-SpCas9 protein monoclonal antibody, a detection kit and application, wherein the heavy chain variable region amino acid sequence of the anti-SpCas9 protein monoclonal antibody is shown as SEQ ID NO. 1, and the light chain variable region amino acid sequence is shown as SEQ ID NO. 2; and a double-antibody sandwich ELISA detection kit is constructed by taking the monoclonal antibody as a capture antibody and an anti-SpCas9 protein polyclonal antibody as a detection antibody. The ELISA detection kit has the advantages of high sensitivity, strong specificity, good repeatability, high-throughput and rapid detection, can accurately quantify the expression and residual amount of SpCas9 protein in a gene editing biological sample, and provides strong support for the application and supervision of CRISPR / Cas9 gene editing technology.